What Does It Mean to Have High-Risk Multiple Myeloma? | Myeloma in a Minute (https://www.myeloma.org/videos/does-it-mean-have-high-risk-multiple-myeloma-myeloma-minute)

What Does It Mean to Have High-Risk Multiple Myeloma? | Myeloma in a Minute 


What does it mean when your doctor says you have high-risk multiple myeloma? In this Myeloma in a Minute video, IMF Medical Advisor Dr. Joseph Mikhael explains high-risk myeloma in simple terms for patients and care partners.


Myeloma is a disease of great spectrum. Some patients have slow-growing disease they live with for many years, while others have more aggressive disease that tends to come back (relapse) more quickly. Dr. Mikhael explains how the myeloma community recently agreed on five parameters that define high-risk multiple myeloma, and why patients with high-risk disease typically need combination therapies given for longer periods of time. Most importantly, he shares that high-risk myeloma is not a death sentence: thanks to major progress in treatment, patients with high-risk multiple myeloma are living longer than ever.

Have more questions about multiple myeloma? Leave them in the comments using #AskTheIMF.

Subscribe for weekly updates on myeloma research, treatment, and patient support. Learn more about multiple myeloma and trusted patient resources at myeloma.org (https://www.myeloma.org/).

Have a question that needs more personalized support? Call us! We’re here for you. The IMF’s InfoLine is available to answer your myeloma-related questions and concerns. Call us at 1-818-487-7455, email us at [email protected] (mailto:[email protected]), or schedule your call at a time that works for you at: myeloma.org/infoline (https://www.myeloma.org/infoline). 

 

Video
View the Transcript

Dr. Joe:

What does it actually mean when someone is told they have high risk multiple myeloma? Hi everybody, Dr. Joe here from the International Myeloma Foundation, and I'm going to try to explain high risk multiple myeloma in a minute or less.

Myeloma is a disease of great spectrum. Some patients have very slow growing disease that they can live with for many, many years, and others have more aggressive disease that tends to come back more quickly. That's what we call high risk disease. It's been defined in different ways over the years. More recently, we came together as a myeloma community and set five different parameters that you can look up that define high risk multiple myeloma.

But the key point is that when patients have high risk myeloma, we want to approach the disease extra carefully. Patients typically need combination therapies given for longer periods of time to keep the disease down because it has that horsepower that it can come back more aggressively. That being said, I don't want you to think that high risk myeloma is a death sentence. We have made huge progress in this disease and in high risk forms of the disease where patients are living longer than ever with high risk multiple myeloma.

Have more questions about multiple myeloma? Drop them in the box below using the hashtag ask the IMF.

 

Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO

International Myeloma Foundation Medical Advisor 
TGen, City of Hope Cancer Center—Phoenix, AZ, USA

Dr Mikhael is a Professor in the Clinical Genomics and Therapeutics Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Director of Myeloma research at the HonorHealth Research Institute in Scottsdale, Arizona. Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom’s macroglobulinemia. He is the PI of many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations.

Dr. Mikhael recently served as the Chief Medical Officer of the International Myeloma Foundation (IMF) from 2018 to 2026 – he now serves as Medical Advisor to the IMF to provide guidance and strategic input in areas such as patient education, health disparities, collaboration with partners, international research, and publications.

Dr Mikhael has published over 200 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr. Mikhael is deeply committed to health disparities in myeloma and is the chair of the Diversity, Equity and Inclusion Council at TGen. Dr. Mikhael is heavily involved in training future researchers and mentors junior faculty worldwide. Dr. Mikhael is an active member of the International Myeloma Working Group (IMWG) and recently led the ASCO guidelines in myeloma. Dr. Mikhael also serves as the Treasurer on the executive of the American Society of Hematology.

Dr. Mikhael did his medical training in Canada, including a fellowship in Multiple Myeloma at the Princess Margaret Hospital in Toronto. He also obtained his master’s degree in education from the University of Toronto. He then worked at the Mayo Clinic Arizona as a Hematologist from 2008-2018.
 

Tag #AsktheIMF to Ask Your Questions on Social Media!


Facebook: @myeloma (https://www.facebook.com/myeloma) | Instagram: @IMFmyeloma (https://www.instagram.com/imfmyeloma/) | Twitter/X: @IMFmyeloma (https://www.twitter.com/IMFmyeloma)

See all of our social media channels at linktr.ee/myeloma (https://linktr.ee/myeloma)

 


Source URL: https://www.myeloma.org/videos/does-it-mean-have-high-risk-multiple-myeloma-myeloma-minute